HLA is certainly worth keeping an eye on.
With roll-ups I think statutory EPS is the key share price driver.
Items such as new share issues to support acquisitions, acquisition costs, etc are all common items incurred every year to support growth. They are not one-offs.
So a singular focus on EBITDA does not tell the true picture.
On my watch list.
Gosouth
